JAGUAR HEALTH, INC. Fair Value, Option, Aggregate Differences, Long-term Debt Instruments
JAGUAR HEALTH, INC. (JAGX) had Fair Value, Option, Aggregate Differences, Long-term Debt Instruments of $2.74 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments · last filed 2023-08-14
- 2023-06-30: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $2.74M.
- 2023-03-31: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $1.98M.
- 2022-12-31: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $1.62M.
- 2022-09-30: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $946.00K.
| Period end | Fair Value, Option, Aggregate Differences, Long-term Debt Instruments | Fair Value, Option, Aggregate Differences, Long-term Debt Instruments as first filed |
|---|---|---|
| 2023-06-30 | $2.74M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.98M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $1.62M 10-K · filed 2023-03-24 | |
| 2022-09-30 | $946.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.12M 10-Q · filed 2022-08-22 | |
| 2022-03-31 | $1.83M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.60M 10-K · filed 2023-03-24 | $1.82M 10-K · filed 2022-03-11 |
| 2021-09-30 | $1.50M 10-Q · filed 2021-11-17 | |
| 2021-06-30 | $933.00K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $452.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |